The number of CD34 þ cells infused influences hematologic recovery after transplantation. Limited data suggest that cell dose should be based on ideal (IBW) rather than actual (ABW) body weight for autotransplantation, but none in allografts. We compared the correlation between recovery to 0.5 Â 10 9 /l neutrophils and the CD34 þ cell dose based upon ABW and IBW in 78 allograft recipients. ABW was X25% over IBW in 47% of patients. The median CD34 þ cell dose was 5.1 Â 10 6 /kg IBW and 4.4 Â 10 6 /kg ABW. The time to neutrophil recovery was 8-26 days (median 12). There was a stronger inverse correlation between CD34 þ cell dose/IBW and neutrophil recovery (r 2 ¼ 0.160; Po0.0001) than between CD34 þ cell dose/ABW and neutrophil recovery (r 2 ¼ 0.138; P ¼ 0.001). When neutrophil recovery in patients receiving o3 or o5 Â 10 6 CD34 þ cells/kg was compared to those receiving X3 or X5 Â 10 6 CD34 þ cells/kg, respectively, separately by IBW and ABW, the magnitude and significance of the differences were greater for IBW-based comparisons. These data suggest the CD34 þ cell dose based on IBW is a better predictor of neutrophil recovery after allografting. Further work in a larger, more homogeneous group of patients is required to confirm this observation.
tation; CD34 þ cells; engraftment; myeloid recovery; weight The progenitor cell content of an allogeneic graft, which used to be measured in terms of the number of nucleated cells in the past, 1,2 is now measured in terms of the number of CD34 þ cells. [3] [4] [5] [6] The progenitor cell dose, expressed as the number of cells per unit recipient body weight, is an important determinant of the speed of hematologic recovery 3, 4, 7 as well as transplant-related mortality (TRM) and disease-free survival (DFS).
1,2,4,7,8 However, whether ideal (IBW) or actual (ABW) body weight should be used for this calculation is unknown. The majority of reports do not specify the basis on which the cell dose was based. In the past, some members of the current group have always used ABW for these calculations at other institutions, 2, 5, 7, 8 although this has never been explicitly specified in any of the publications.
Limited data suggest that the progenitor cell dose expressed by IBW is a better predictor of myeloid recovery after autotransplantation than ABW. 9 This study utilized the nucleated cell count and CFU-GM as a measure of progenitor cells. CD34 þ cell data were limited, and not consistent. We have analyzed recently CD34 þ cell dose data in a larger number of autografted patients and have found IBW to be superior to ABW in predicting neutrophil recovery. 10 Cell doses have usually been expressed in terms of IBW at Northwestern. 10 This retrospective study was undertaken to determine the correlation between engraftment and CD34 þ cell dose expressed on the basis of ABW and IBW in allograft recipients.
Patients and methods
A total of 78 adult patients with malignant diseases who were allografted from HLA-identical sibling donors in the Hematopoietic Stem Cell Transplant Program of the Division of Hematology/Oncology at the Northwestern University Medical School and the Northwestern Memorial Hospital in Chicago between 1995 and 2001, who had adequate ABW and IBW data available, were studied (10 patients with missing data or death before engraftment were excluded). Table 1 shows the patient characteristics.
Bone marrow was harvested from the iliac crest using standard techniques. Stem cells were collected using the Fenwal CS 3000 Plus cell separator (Baxter, Deerfield, IL USA) or the Cobe Spectra cell separator (Gambro BCT, Lakewood, CO, USA) 11, 12 after mobilization with filgrastim alone at a dose of 5-10 mg/kg daily; with apheresis commencing on the fourth or fifth day of G-CSF therapy.
Patients allografted using blood-derived stem cells received unmanipulated cells, whereas those allografted with a combination of marrow and blood received unmanipulated marrow and CD34-selected blood stem cells. CD34 þ cell content of the collected product was enumerated using standard techniques 13 prior to transplantation. IBW (kg) was calculated by a standard formula using sex and height: 50 þ {2.3 Â (height in inchesÀ60)} for males and 45.5 þ {2.3 Â (height in inchesÀ60)} for females. 14 The conditioning regimens used were standard, and included busulfan-cyclophosphamide, cyclophosphamidetotal body irradiation, etoposide-total body irradiation, and cyclophosphamide-etoposide-total body irradiation. Two patients with myeloma, with a prior history of autotransplantation, received a reduced intensity regimen (100 mg/m 2 melphalan). The source of stem cells was unmanipulated bone marrow, unmanipulated marrow with added CD34-selected G-CSF-mobilized blood, or G-CSFmobilized blood alone. GVHD prophylaxis included cyclosporine alone, cyclosporine with methotrexate, and cyclosporine-prednisone. Myeloid growth factors were administered in the post transplant period to 69 of 78 patients; 67 received G-CSF, whereas two patients received GM-CSF as specified in the protocol they were enrolled on. The first day with an absolute neutrophil count (ANC) of X0.5 Â 10 9 /l was considered the day of engraftment. 15 
Statistical methods
The inverse curve fit technique was used to determine the correlation between the CD34 þ cell doses (by IBW and ABW separately) and days to ANC recovery. Time to ANC recovery was compared for various CD34 þ cell dose cutoff values (o3 vs X3 and o5 vs X5) separately for ABW and IBW. The Wilcoxon rank-sum test was used to compare time to engraftment. Characteristics of the groups were compared using the w 2 or the Fisher's exact test.
Results
The target CD34 þ cell dose was 2 Â 10 6 /kg IBW, and was met in 70 of 78 (90%) patients. All patients achieved neutrophil recovery. The median time to ANC 0.5 Â 10 9 /l was 12 days (range, 8-26 days). Figures 1 and 2 show that the correlation between the CD34 þ cell dose and time to ANC recovery was statistically significant. This correlation was stronger for IBW (higher r 2 value) than for ABW. Table 2 shows that within the two CD34 þ cell dose cutoff levels studied, the lower CD34 þ cell dose was Figures represent medians and ranges.
Ideal or actual body weight to calculate cell dose? J Cilley et al associated with slower engraftment. This difference was significant for both cutoff level comparisons based on IBW, and significant for only one of the ABW cutoff levels. For each cutoff level comparison, the difference was more significant when based upon IBW (ie a lower P-value) than ABW. The difference between median was greater when the comparison was based upon IBW than by ABW. Table 2 also shows that the distribution of other variables affecting engraftment (source of stem cells, growth factor administration, and methotrexate) did not change significantly as the calculation basis was changed from IBW to ABW, suggesting that the differences between the comparisons were most likely due to the basis of the comparison (ABW/ IBW) than any differences in characteristics.
Discussion
Our data show that there is a better correlation between CD34 þ cell dose based upon IBW and neutrophil engraftment compared with the cell dose based upon ABW and engraftment after allogeneic transplantation (Figures 1 and 2) , and that CD34 þ cell dose thresholds based upon IBW provide better discrimination between more rapid and less rapid engraftment (Table 2) . These data are consistent with our observations in autografted patients. 10 Was there a reason to expect that the findings would differ in allografted patients? Probably not, since the endpoint under consideration is simple (recovery to 0.5 Â 10 9 /l neutrophils). However, we felt it was important to study this separately in allograft recipients for several reasons: CD34 þ cell dose thresholds are different in autograft and allograft recipients, allograft recipients are more susceptible to myelosuppression (because of infections and the influence of drugs such as methotrexate post transplant), and allograft recipients still receive bone marrow sometimes. Also, it was essential to validate the observation in a different group of patients.
There are shortcomings to this analysis. Most importantly, the patient population was heterogeneous in terms of stem cell source, methotrexate post transplant, and growth factor administration. However, the correlation comparisons (Figures 1 and 2) would not be expected to be influenced by heterogeneity. The distribution of patients between categories (Table 2 ) was comparable when the basis for calculation was changed from IBW to ABW. We believe therefore that our data are suggestive. However, they ought to be confirmed in a larger group of more uniformly treated patients.
This finding is of no consequence for patients from whose donors an excellent quantity of stem cells is collected rapidly. However, for donors who require a number of aphereses to reach a certain target cell dose and in whose recipients ABW exceeds IBW by a significant margin, measuring CD34 þ cells based upon IBW would help cut down the number of apheresis procedures while ensuring that enough cells were available for prompt engraftment.
Similarly, if a substantial quantity of stem cells is available for an allograft, a calculation based upon IBW may permit an adequate quantity of stem cells to be infused while retaining a reasonable number of stem cells for potential future use such as an additional stem cell infusion for immunotherapy of relapsed or persistent disease.
It has also been shown that the CD34 þ cell dose based upon IBW is a better predictor of TRM and DFS; 16 an observation that is consistent with the findings here.
Based on these observations, we suggest that IBW should be evaluated further as the standard for measurement in clinical practice as well as reporting data for allogeneic blood and marrow transplantation. 
